Sigachi Industries Limited, a key player in the pharmaceutical sector, has announced a strategic investment of up to USD 1 million to establish a state-of-the-art Research and Development (R&D) facility in Hyderabad, India. This move aims to accelerate innovation and enhance the company’s long-term growth prospects.
The new R&D facility is designed to optimize Active Pharmaceutical Ingredient (API) production by incorporating advanced systems and meeting global regulatory standards. With a team of 15-20 skilled scientists, Sigachi plans to strengthen its product pipeline, focusing on the development of both existing and new molecules for regulated markets. The initiative also aligns with Sigachi’s vision to drive high-value innovation and enhance synthesis and analytical processes, which are crucial in API development.
This investment will also fuel the company’s plans to introduce six new CEPs (Certificate of Suitability) within the next six months, further solidifying its market leadership. The facility will foster synergies by enabling API manufacturing and regulatory filings under one roof, streamlining Sigachi’s pharmaceutical product portfolio.
Amit Raj Sinha, Managing Director and CEO of Sigachi Industries Limited, emphasized, “Our heightened commitment to R&D reflects our strategic vision for innovation and excellence. By investing more into R&D, we are not only accelerating product development but also strengthening Sigachi’s growth trajectory.”
